The New England journal of medicine, 2023-06, Vol.388 (26), p.2444-2455
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- Ist Teil von
- The New England journal of medicine, 2023-06, Vol.388 (26), p.2444-2455
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- In two phase 3 trials, mirikizumab, a p19-directed anti–interleukin-23 antibody, was superior to placebo with regard to clinical remission of ulcerative colitis at 12 weeks (induction) and 40 weeks (maintenance).
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2207940Titel-ID: cdi_proquest_miscellaneous_2831296927
- Format
- –
- Schlagworte
- Administration, Intravenous, Adult, Anti-Inflammatory Agents, Non-Steroidal - administration & dosage, Anti-Inflammatory Agents, Non-Steroidal - adverse effects, Anti-Inflammatory Agents, Non-Steroidal - immunology, Anti-Inflammatory Agents, Non-Steroidal - therapeutic use, Arthralgia, Cancer, Clinical Medicine, Clinical Medicine General, Clinical trials, Colitis, Ulcerative - drug therapy, Colorectal carcinoma, Crohns disease, Cytokines, Double-Blind Method, Double-blind studies, Endoscopy, FDA approval, Gastroenterology, Herpes zoster, Herpes Zoster - chemically induced, Herpes Zoster - etiology, Humans, Induction Chemotherapy - adverse effects, Induction Chemotherapy - methods, Induction therapy, Inflammatory Bowel Disease, Interleukin 23, Maintenance Chemotherapy - adverse effects, Maintenance Chemotherapy - methods, Monoclonal antibodies, Opportunist infection, Opportunistic Infections - chemically induced, Opportunistic Infections - etiology, Patients, Placebos, Remission, Remission (Medicine), Remission Induction, Rhinopharyngitis, Subcutaneous Absorption, Ulcerative colitis